DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Valstar (Valrubicin) - Summary

 
 



VALSTAR SUMMARY

Valrubicin (N-trifluoroacetyladriamycin-14-valerate), a semisynthetic analog of the anthra-cycline doxorubicin, is a cytotoxic agent.

VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.


See all Valstar indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Valstar (Valrubicin)

Urine test could help predict recurrence of bladder cancer
Source: Urology / Nephrology News From Medical News Today [2014.04.01]
Bladder cancer is characterized by a high risk of recurrence, but now, researchers have developed a urine test that accurately predicts tumor reappearance.

Certain genetic variants may put bladder cancer patients at increased risk of cancer recurrence
Source: Urology / Nephrology News From Medical News Today [2014.03.26]
In the Western world, bladder cancer is the fourth most common cancer in men and the eighth most common in women, with many patients experiencing recurrence after treatment.

Gallbladder Cancer
Source: MedicineNet Gallstones Specialty [2014.03.19]
Title: Gallbladder Cancer
Category: Diseases and Conditions
Created: 4/2/2008 12:00:00 AM
Last Editorial Review: 3/19/2014 12:00:00 AM

Bladder Cancer Pictures Slideshow: Symptoms, Stages & Treatment
Source: MedicineNet Bladder Cancer Specialty [2014.03.05]
Title: Bladder Cancer Pictures Slideshow: Symptoms, Stages & Treatment
Category: Slideshows
Created: 2/8/2012 12:00:00 AM
Last Editorial Review: 3/5/2014 12:00:00 AM

Bladder Cancer
Source: MedicineNet Biological Therapy Specialty [2013.11.26]
Title: Bladder Cancer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/26/2013 12:00:00 AM

more news >>

Published Studies Related to Valstar (Valrubicin)

Factors affecting valrubicin response in patients with bacillus Calmette-Guerin-refractory bladder carcinoma in situ. [2011.05]
OBJECTIVE: Patients with bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the bladder are candidates for intravesical (IVe) valrubicin. This post-hoc analysis of data from the pivotal phase 3, prospective, open-label study of valrubicin evaluated the effects of patient characteristics and past treatments on the response to valrubicin... CONCLUSIONS: In these patients with BCG-refractory CIS, complete responders to valrubicin did not differ significantly from partial or nonresponders in the number of prior courses or instillations. The results suggest that therapy with valrubicin may be considered in appropriate candidates who have not responded to prior therapies. Cystectomy should be reconsidered when valrubicin treatment fails.

Topical application of valrubicin has a beneficial effect on developing skin tumors. [2010.08]
Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact...

Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. [2010.02]
Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a trademarked Valstar sterile solution for the treatment of bladder cancer. Valrubicin has shown an excellent therapeutic potential with minimal toxicity.

more studies >>

Clinical Trials Related to Valstar (Valrubicin)

Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma [Recruiting]
The purpose of this study is to learn more about how well the drug valrubicin (VALSTARŪ) works to help treat the patient's cancer when administered through a nephrostomy tube inserted through their back into their kidney. The study is also being done to determine how safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in which the drug is eliminated from the human body (Pharmacokinetics or PK).

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer [Not yet recruiting]
The use of a designed viral vector that can destroy cancer cells while leaving normal cells largely unharmed. The virus also stimulates an immunological response by producing a special factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It forms the hypothesis that this regimen may be used for people who have failed current forms of treatment and are recommended for cystectomy. It is with hope that this novel therapy will be able to delay or potentially avoid cystectomy for this patient population. Bladder instillation of this agent causes little long lasting side effects and may drastically improve the stimulation of the immune system for local cancer cell death as well as destroying those tumor cells that may have travelled to regional lymph nodes or distant organs.

more trials >>


Page last updated: 2014-04-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012